Cargando…
Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020
BACKGROUND: Emerging data suggest that second-generation influenza vaccines with higher hemagglutinin (HA) antigen content and/or different production methods may induce stronger antibody responses to HA than standard-dose egg-based influenza vaccines in adults. We compared antibody responses to hig...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249269/ https://www.ncbi.nlm.nih.gov/pubmed/37305842 http://dx.doi.org/10.1093/ofid/ofad223 |
| _version_ | 1785055524666998784 |
|---|---|
| author | Naleway, Allison L Kim, Sara S Flannery, Brendan Levine, Min Z Murthy, Kempapura Sambhara, Suryaprakash Gangappa, Shivaprakash Edwards, Laura J Ball, Sarah Grant, Lauren Zunie, Tnelda Cao, Weiping Gross, F Liaini Groom, Holly Fry, Alicia M Hunt, Danielle Jeddy, Zuha Mishina, Margarita Wesley, Meredith G Spencer, Sarah Thompson, Mark G Gaglani, Manjusha Dawood, Fatimah S |
| author_facet | Naleway, Allison L Kim, Sara S Flannery, Brendan Levine, Min Z Murthy, Kempapura Sambhara, Suryaprakash Gangappa, Shivaprakash Edwards, Laura J Ball, Sarah Grant, Lauren Zunie, Tnelda Cao, Weiping Gross, F Liaini Groom, Holly Fry, Alicia M Hunt, Danielle Jeddy, Zuha Mishina, Margarita Wesley, Meredith G Spencer, Sarah Thompson, Mark G Gaglani, Manjusha Dawood, Fatimah S |
| author_sort | Naleway, Allison L |
| collection | PubMed |
| description | BACKGROUND: Emerging data suggest that second-generation influenza vaccines with higher hemagglutinin (HA) antigen content and/or different production methods may induce stronger antibody responses to HA than standard-dose egg-based influenza vaccines in adults. We compared antibody responses to high-dose egg-based inactivated (HD-IIV3), recombinant (RIV4), and cell culture–based (ccIIV4) vs standard-dose egg-based inactivated influenza vaccine (SD-IIV4) among health care personnel (HCP) aged 18–65 years in 2 influenza seasons (2018–2019, 2019–2020). METHODS: In the second trial season, newly and re-enrolled HCPs who received SD-IIV4 in season 1 were randomized to receive RIV4, ccIIV4, or SD-IIV4 or were enrolled in an off-label, nonrandomized arm to receive HD-IIV3. Prevaccination and 1-month-postvaccination sera were tested by hemagglutination inhibition (HI) assay against 4 cell culture propagated vaccine reference viruses. Primary outcomes, adjusted for study site and baseline HI titer, were seroconversion rate (SCR), geometric mean titers (GMTs), mean fold rise (MFR), and GMT ratios that compared vaccine groups to SD-IIV4. RESULTS: Among 390 HCP in the per-protocol population, 79 received HD-IIV3, 103 RIV4, 106 ccIIV4, and 102 SD-IIV4. HD-IIV3 recipients had similar postvaccination antibody titers compared with SD-IIV4 recipients, whereas RIV4 recipients had significantly higher 1-month-postvaccination antibody titers against vaccine reference viruses for all outcomes. CONCLUSIONS: HD-IIV3 did not induce higher antibody responses than SD-IIV4, but, consistent with previous studies, RIV4 was associated with higher postvaccination antibody titers. These findings suggest that recombinant vaccines rather than vaccines with higher egg-based antigen doses may provide improved antibody responses in highly vaccinated populations. |
| format | Online Article Text |
| id | pubmed-10249269 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102492692023-06-09 Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 Naleway, Allison L Kim, Sara S Flannery, Brendan Levine, Min Z Murthy, Kempapura Sambhara, Suryaprakash Gangappa, Shivaprakash Edwards, Laura J Ball, Sarah Grant, Lauren Zunie, Tnelda Cao, Weiping Gross, F Liaini Groom, Holly Fry, Alicia M Hunt, Danielle Jeddy, Zuha Mishina, Margarita Wesley, Meredith G Spencer, Sarah Thompson, Mark G Gaglani, Manjusha Dawood, Fatimah S Open Forum Infect Dis Major Article BACKGROUND: Emerging data suggest that second-generation influenza vaccines with higher hemagglutinin (HA) antigen content and/or different production methods may induce stronger antibody responses to HA than standard-dose egg-based influenza vaccines in adults. We compared antibody responses to high-dose egg-based inactivated (HD-IIV3), recombinant (RIV4), and cell culture–based (ccIIV4) vs standard-dose egg-based inactivated influenza vaccine (SD-IIV4) among health care personnel (HCP) aged 18–65 years in 2 influenza seasons (2018–2019, 2019–2020). METHODS: In the second trial season, newly and re-enrolled HCPs who received SD-IIV4 in season 1 were randomized to receive RIV4, ccIIV4, or SD-IIV4 or were enrolled in an off-label, nonrandomized arm to receive HD-IIV3. Prevaccination and 1-month-postvaccination sera were tested by hemagglutination inhibition (HI) assay against 4 cell culture propagated vaccine reference viruses. Primary outcomes, adjusted for study site and baseline HI titer, were seroconversion rate (SCR), geometric mean titers (GMTs), mean fold rise (MFR), and GMT ratios that compared vaccine groups to SD-IIV4. RESULTS: Among 390 HCP in the per-protocol population, 79 received HD-IIV3, 103 RIV4, 106 ccIIV4, and 102 SD-IIV4. HD-IIV3 recipients had similar postvaccination antibody titers compared with SD-IIV4 recipients, whereas RIV4 recipients had significantly higher 1-month-postvaccination antibody titers against vaccine reference viruses for all outcomes. CONCLUSIONS: HD-IIV3 did not induce higher antibody responses than SD-IIV4, but, consistent with previous studies, RIV4 was associated with higher postvaccination antibody titers. These findings suggest that recombinant vaccines rather than vaccines with higher egg-based antigen doses may provide improved antibody responses in highly vaccinated populations. Oxford University Press 2023-04-21 /pmc/articles/PMC10249269/ /pubmed/37305842 http://dx.doi.org/10.1093/ofid/ofad223 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Major Article Naleway, Allison L Kim, Sara S Flannery, Brendan Levine, Min Z Murthy, Kempapura Sambhara, Suryaprakash Gangappa, Shivaprakash Edwards, Laura J Ball, Sarah Grant, Lauren Zunie, Tnelda Cao, Weiping Gross, F Liaini Groom, Holly Fry, Alicia M Hunt, Danielle Jeddy, Zuha Mishina, Margarita Wesley, Meredith G Spencer, Sarah Thompson, Mark G Gaglani, Manjusha Dawood, Fatimah S Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 |
| title | Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 |
| title_full | Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 |
| title_fullStr | Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 |
| title_full_unstemmed | Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 |
| title_short | Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture–Based Influenza Vaccines Compared With Standard-Dose Egg-Based Influenza Vaccine Among Health Care Personnel Aged 18–65 Years in 2019–2020 |
| title_sort | immunogenicity of high-dose egg-based, recombinant, and cell culture–based influenza vaccines compared with standard-dose egg-based influenza vaccine among health care personnel aged 18–65 years in 2019–2020 |
| topic | Major Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249269/ https://www.ncbi.nlm.nih.gov/pubmed/37305842 http://dx.doi.org/10.1093/ofid/ofad223 |
| work_keys_str_mv | AT nalewayallisonl immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT kimsaras immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT flannerybrendan immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT levineminz immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT murthykempapura immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT sambharasuryaprakash immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT gangappashivaprakash immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT edwardslauraj immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT ballsarah immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT grantlauren immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT zunietnelda immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT caoweiping immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT grossfliaini immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT groomholly immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT fryaliciam immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT huntdanielle immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT jeddyzuha immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT mishinamargarita immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT wesleymeredithg immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT spencersarah immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT thompsonmarkg immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT gaglanimanjusha immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 AT dawoodfatimahs immunogenicityofhighdoseeggbasedrecombinantandcellculturebasedinfluenzavaccinescomparedwithstandarddoseeggbasedinfluenzavaccineamonghealthcarepersonnelaged1865yearsin20192020 |